Moreover, CLL sub-clones carrying TP53 mutations can be positively selected upon treatment, ultimately becoming the prevalent expansion of an initially minor mutant component 4,17,21,22. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.